Systemic Antifungal Therapy for Invasive Pulmonary Infections
- PMID: 36836260
- PMCID: PMC9966409
- DOI: 10.3390/jof9020144
Systemic Antifungal Therapy for Invasive Pulmonary Infections
Abstract
Antifungal therapy for pulmonary fungal diseases is in a state of flux. Amphotericin B, the time-honored standard of care for many years, has been replaced by agents demonstrating superior efficacy and safety, including extended-spectrum triazoles and liposomal amphotericin B. Voriconazole, which became the treatment of choice for most pulmonary mold diseases, has been compared with posaconazole and itraconazole, both of which have shown clinical efficacy similar to that of voriconazole, with fewer adverse events. With the worldwide expansion of azole-resistant Aspergillus fumigatus and infections with intrinsically resistant non-Aspergillus molds, the need for newer antifungals with novel mechanisms of action becomes ever more pressing.
Keywords: antifungal drug; antifungal resistance; invasive aspergillosis; mucormycosis.
Conflict of interest statement
Dr. Ben-Ami has served on advisory boards for Pfizer and Merck and received compensation from Teva and Gilead for lectures.
Similar articles
-
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).J Antimicrob Chemother. 2000 Aug;46(2):229-34. doi: 10.1093/jac/46.2.229. J Antimicrob Chemother. 2000. PMID: 10933645
-
Clinical utility of antifungal susceptibility testing in patients with fungal rhinosinusitis.Indian J Med Microbiol. 2021 Jul;39(3):328-333. doi: 10.1016/j.ijmmb.2021.04.005. Epub 2021 Apr 24. Indian J Med Microbiol. 2021. PMID: 33906748
-
Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.Clin Microbiol Infect. 2001 Mar;7(3):130-7. doi: 10.1046/j.1469-0691.2001.00220.x. Clin Microbiol Infect. 2001. PMID: 11318811
-
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Drugs. 2009. PMID: 19275278 Review.
-
New antifungal agents.Dermatol Clin. 2003 Jul;21(3):565-76. doi: 10.1016/s0733-8635(03)00024-x. Dermatol Clin. 2003. PMID: 12956208 Review.
Cited by
-
Special Issue "Diagnosis and Treatment of Invasive Pulmonary Fungal Infections".J Fungi (Basel). 2023 Jul 13;9(7):744. doi: 10.3390/jof9070744. J Fungi (Basel). 2023. PMID: 37504732 Free PMC article.
-
Characterization and expression of fungal defensin in Escherichia coli and its antifungal mechanism by RNA-seq analysis.Front Microbiol. 2023 Jun 14;14:1172257. doi: 10.3389/fmicb.2023.1172257. eCollection 2023. Front Microbiol. 2023. PMID: 37389349 Free PMC article.
-
Antifungals: From Pharmacokinetics to Clinical Practice.Antibiotics (Basel). 2023 May 9;12(5):884. doi: 10.3390/antibiotics12050884. Antibiotics (Basel). 2023. PMID: 37237787 Free PMC article. Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources